Breaking News

Galena Acquires Orexo Cancer Pain Drug

March 18, 2013

Will sell and distribute Abstral in the U.S.

Galena Biopharma has entered into an agreement with Orexo AB to acquire Abstral (fentanyl) Sublingual Tablets for sale and distribution in the U.S. Galena will pay $10 million upfront and $5 million in the first 12 months of closing, plus royalties and milestones based on sales.
Abstral is a new treatment option for inadequately controlled breakthrough cancer pain (BTcP) in patients who are receiving, and tolerant to, opioid therapy for cancer pain. The Abstral formulation delivers the analgesic power of fentanyl in a sublingual tablet that dissolves under the tongue. It was approved by the FDA in January 2011 and achieved sales of $54 million in Europe by ProStrakan/Kyowa Hakko Kirin in 2012. It’s marketed in Canada by Paladin Labs, and has been filed for approval in Japan by Kyowa Hakko Kirin.
"The acquisition of Abstral diversifies and strengthens our pipeline, providing Galena with an FDA-approved product that will become a cornerstone of our commercial strategy and bring revenues to the company in 2014 to support the development of our pipeline," said Mark J. Ahn, Ph.D., president and chief executive officer of Galena Biopharma. "Galena's launch of Abstral will build relationships with future prescribers of NeuVax, which is currently in Phase III trials in node positive HER2 IHC 1+/2+ breast cancer patients."
"With Galena Biopharma, Orexo has found a very committed partner for Abstral in the U.S., who is well positioned to realize the significant potential that exists for Abstral. I have been impressed by the competence, experience and commitment to Abstral from the Galena Biopharma management team," said Nikolaj Sorensen, president and chief executive officer of Orexo.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks